More than 99 percent of cervical cancers are caused by persistent high-risk HPV infection1 Cervical cancer is nearly 100 percent preventable with proper HPV vaccination, screening and treatment; ...
Every year, over 600,000 women worldwide are diagnosed with cervical cancer and over 340,000 die from this preventable disease, caused by infection with human papillomavirus (HPV). Nine out of 10 ...
New process allows labs to use same Pap test vial instead of transferring sample to new vial, thus simplifying workflow INDIANAPOLIS, June 26, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) ...
ATHENA study shows the cobas HPV Test advances the standard of care by providing valuable information on the risks associated with the genotypes which cause 70 percent of cervical cancer Results from ...
PLEASANTON, Calif., Oct. 11 /PRNewswire/ -- Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) and the German Cancer Research Center (DKFZ) announced today that they have entered into a ...
The HPV self-collection solution allows an individual to collect their own vaginal sample for HPV screening while at a health care facility. The Food and Drug Administration (FDA) has approved Roche’s ...
Multiplex PCR Assay for cobas 4800 system uses self-collected male urine and vaginal swab samples. FDA granted 510(k) clearance for Roche’s cobas® CT/NG Test for detecting Chlamydia trachomatis (CT) ...
Roche, the world's largest biotech company, has launched pre-analytical device cobas p 480 to uncover and summarize primary sample vials used in cytology-based in liquids (LBC) and molecular assays ...
The FINANCIAL — Roche announced on November 3 the commercial availability of the cobas HIV-1, HCV and HCV Genotyping (GT) assays in countries accepting the CE mark. These new molecular diagnostic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback